ELCC 2019 | Current treatment landscape for ALK-positive NSCLC

Marina Garassino

In this video, Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, presents the currently available drugs against ALK-positive treating non-small cell lung cancer (NSCLC): crizotinib, ceritinib, alectinib and brigatinib. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino reports that all agents demonstrate different toxicity profiles and stresses the need for further research in order to single out the most effective drug.

Share this video